Content by illumina

This single test interrogates over 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.

Centralized core facilities and commercial service providers specializing in NGS provide expertise and training for researchers new to the method.

Learn how to successfully use next generation sequencing to gain valuable research insights with the expert help of core laboratories.

Multiomics combines multiple layers of biology to power new discoveries in disease research. 

A conversation with Illumina Distinguished Scientist and Vice President Gary Schroth about the present and future of multiomic technology and applications

Researchers across disciplines combine layers of discovery obtained with accessible NGS-based multiomics approaches.